• Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for USD 1.55 billion upfront.
• Deal includes up to USD 1.1 billion in regulatory and commercial milestone payments, taking total potential consideration to USD 2.65 billion.
• Transaction shifts the company to a cardiovascular focus; proceeds expected to fund EDG-7500 through potential approval.
• Phase 3 initiation for EDG-7500 in hypertrophic cardiomyopathy targeted for Q4 2026; Phase 2 for EDG-15400 in HFpEF remains on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607130830PR_NEWS_USPR_____LA01875) on July 13, 2026, and is solely responsible for the information contained therein.